A First in Human Phase I, Open Label Dose-escalation Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
Latest Information Update: 04 Jan 2024
At a glance
- Drugs MNV 201 (Primary) ; Filgrastim; Plerixafor
- Indications Mitochondrial disorders
- Focus Adverse reactions; First in man
- Sponsors Minovia Therapeutics
- 08 Sep 2021 New trial record